Tobira Therapeutics Inc (TBRA) : Stonepine Capital Management reduced its stake in Tobira Therapeutics Inc by 23.46% during the most recent quarter end. The investment management company now holds a total of 637,567 shares of Tobira Therapeutics Inc which is valued at $2,939,184 after selling 195,410 shares in Tobira Therapeutics Inc , the firm said in a disclosure report filed with the SEC on Aug 10, 2016.Tobira Therapeutics Inc makes up approximately 3.14% of Stonepine Capital Management’s portfolio.
Other Hedge Funds, Including , Blackrock Institutional Trust Company N.a. boosted its stake in TBRA in the latest quarter, The investment management firm added 36,817 additional shares and now holds a total of 76,401 shares of Tobira Therapeutics Inc which is valued at $352,209.Blair William Coil reduced its stake in TBRA by selling 17,115 shares or 45.97% in the most recent quarter. The Hedge Fund company now holds 20,115 shares of TBRA which is valued at $87,500.California State Teachers Retirement System boosted its stake in TBRA in the latest quarter, The investment management firm added 12,951 additional shares and now holds a total of 18,578 shares of Tobira Therapeutics Inc which is valued at $76,727. Simplex Trading added TBRA to its portfolio by purchasing 2,302 company shares during the most recent quarter which is valued at $25,322.
Tobira Therapeutics Inc opened for trading at $4.78 and hit $5 on the upside on Friday, eventually ending the session at $4.87, with a gain of 2.10% or 0.1 points. The heightened volatility saw the trading volume jump to 2,86,208 shares. Company has a market cap of $92 M.
Many Wall Street Analysts have commented on Tobira Therapeutics Inc. Cantor Fitzgerald Initiated Tobira Therapeutics Inc on Jul 6, 2016 to “Buy”, Price Target of the shares are set at $27.
Tobira Therapeutics Inc. formerly Regado BioSciences Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat liver disease inflammation fibrosis and human immunodeficiency virus (HIV). The Companys lead product candidate cenicriviroc (CVC) is an immunomodulator that can be used to treat a number of diseases including non-alcoholic steatohepatitis (NASH) kidney fibrosis HIV-1 and others. The Company is engaged in clinical studies for CVC including the CENTAUR Study an international randomized Phase IIb study of CVC and placebo in patients with NASH and liver fibrosis (NCT02217475). The Company has initiated ORION a Phase IIa Study of Cenicriviroc in obese patients with fatty liver disease. It is also engaged in the Phase I pioglitazone safety combination study. NASH is a type of non-alcoholic fatty liver disease or NAFLD. NAFLD is a liver disease and is associated with obesity and type-2 diabetes.